Videos

Experts review 3 clinical cases, discuss treatment options and relevant clinical trials in GIST.

Hematology/oncology expert, John P. Leonard, MD, describes the rationale for treating an elderly patient with relapsed/refractory follicular lymphoma with a PI3K inhibitor in the third-line setting.

Luca Bertamini, MD, a hematologist oncologist at the Università delgi Studi di Torino, discusses outcomes and prognosis for patients with high-risk multiple myeloma.

Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.

Leora Horn, MD, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.

Yi-Bin Chen, MD, comments on the need for improvements in patient assessment tools, measurements of response, and therapeutic agents for the management of acute GvHD in the future.

Yi-Bin Chen, MD, considers potential treatment options for steroid-refractory aGvHD and examines the results of the phase 3 REACH2 study of ruxolitinib.

Yi-Bin Chen, MD, discusses diagnostic criteria and measurements of response as they relate to the case of a 50-year-old woman with steroid-refractory acute GvHD.

Yi-Bin Chen, MD, defines acute graft-versus-host disease (aGvHD) as a complication of allogeneic transplant, discusses the clinical risk factors, and reviews prophylactic treatment options.

Yi-Bin Chen, MD, gives insight into the current accuracy of predictive prognostics and the potential use of biomarkers to risk stratify patients with acute GvHD in the future.

Yi-Bin Chen, MD, provides an overview of the case of a 50-year-old woman with steroid-refractory acute GvHD, including initial presentation, clinical work-up, and treatment.

Yi-Bin Chen, MD, reviews the case of a 50-year-old woman with steroid-refractory acute graft versus host disease (aGvHD) following allogeneic transplant and provides a discussion on treatment considerations for patients with aGvHD.

Othman Al-Sawaf, MD, discusses an analysis of minimal residual disease in patients with chronic lymphocytic leukemia given venetoclax and obinutuzumab on the CLL14.

Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.

Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.

Curtis Lachowiez, MD, discusses the interim analysis of the phase 1b/2 study of venetoclax in combination with standard intensive acute myeloid leukemia induction plus consolidation therapy with the FLAG-IDA regimen as treatment of patients with newly diagnosed or relapsed/refractory AML

Adam M. Brufsky, MD, PhD, discusses the use of neoadjuvant therapy for patients with triple–negative breast cancer.

Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.

Markus Moehler, MD, PhD, discusses the survival outcomes of nivolumab in combination with chemotherapy in patients with advanced gastric cancer.

Brian I. Rini, MD, discusses the dosing of nivolumab plus ipilimumab for patients with renal cell carcinoma.

Hossein Borghaei, DO, MS, discusses some adverse events (AEs) associated with the use of immunotherapy for lung cancer.

Sergio Giralt, MD, discusses the current unmet medical needs for patients with relapsed/refractory acute myeloid leukemia.

Yi Lin, MD, PhD, explains the potential impact the approval of idecabtagene vicleucel could bring to the multiple myeloma field.

Lucia Masarova, MD, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST trial in patients with myelofibrosis.

Shana Wingo, MD, talks about the challenges of treating patients in the Greater Phoenix, Arizona area.

Kami Maddocks, MD, discusses potential treatments in follicular lymphoma.

Ruth He, MD, grants advice on how to treat patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses potential options for physicians in their treatment of unresectable hepatocellular carcinoma.

Ruth He, MD, acknowledges the current struggles experts face in combatting unresectable hepatocellular carcinoma.

Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.